Viruses and Virus-Like Particles as Nanoplatforms for Vaccines, Diagnostic and Therapeutic Nanomedicine
Deadline for manuscript submissions: 31 December 2024 | Viewed by 86
2. Ivanovsky Institute of Virology, National Research Center of Epidemiology and Microbiology, N.F. Gamaleya of the Russian Ministry of Health, 123098 Moscow, Russia
Interests: bionanotechnology; virology; immunology
Special Issues, Collections and Topics in MDPI journals
Nearly 1030 various viruses co-exist around us. Today, they remain a public health concern. Despite the COVID-19 pandemic being over, SARS-CoV-2 continues to persist and to infect new hosts. However, the available knowledge allows us to use the already isolated viruses and virus-like particles in vaccinology and clinical diagnostics, and for targeted drug delivery.
Rapid progress in virus detection and identification, phylogenetic analysis of full-length genomes, multiplex determination of viral and bacterial pathogens, and fabrication of protein and lipid nanoparticles raises new fundamental questions. Further research into molecular evolution and rearrangements of quasi-species of RNA- and DNA-containing viruses, the possible integration of viral genomic DNA into cellular chromosomes and mitochondrial DNA, innate and adaptive immune responses during natural infection and after vaccination, the interaction of viral factors with the host immune system and cellular proteins, and the evaluation of currently available vaccines against new viral threats is necessary for possible implementation in bio-nanotechnology, vaccinology, drug design, and the development of diagnostic systems for acute and chronic infections with low viral loads of attenuated persistent viruses. Currently, viruses are the best tool for the targeted delivery of drugs in permissive cells with specific surface receptors.
This Special Issue, “Viruses and Virus-Like Particles as Nanoplatforms for Vaccines, Diagnostic and Therapeutic Nanomedicine”, will include selected research and review articles devoted to new approaches for vaccine design, the estimation of possible risks of mRNA vaccines and vector vaccines, describing criteria to select viral antigens for multiplex immunoassays, mechanisms of virus adaptation to their hosts, factors of innate and adaptive immunity, and the possible implementation of attenuated viruses in the packaging and delivery of drugs.
Dr. Olga V. Morozova
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.